Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study
Wang, Sophia , Sarangi, Vivekananda , Link, Brian K. , Inwards, David J. , Witzig, Thomas E. , Rothman, Nathaniel , Asmann, Yan W. , Witzig, T.E. , Asmann, Yan, Cerhan, James R , Link, Brian K , Wang, Sophia S , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Feldman, Andrew L. , Cozen, Wendy , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | February 28, 2019 | Volume: 94 | Issue: 6 | Pages: No page available

10.1002/ajh.25451 | PMID 30815899 Get It

Percutaneous Pedicle Screw Fixation Alone Versus Debridement and Fusion Surgery for the Treatment of Early Spinal Tuberculosis: A Retrospective Cohort Study
Guo, Song , Zhu, Kai , Zhang, Shuya , Yang, Mingjie , Yan, Meijun , Li, Xinhua , Pan, Jie , Li, Lijun , Wang, Zhigang , Tan, Jun , Ma, Bin

Mayo Clinic

Medical Science Monitor | February 27, 2019 | Volume: 25 | Issue: No issue available | Pages: 1549-1557

10.12659/msm.912538 | PMID 30811378 Get It

MetaMarker: a pipeline for de novo discovery of novel metagenomic biomarkers
Tran, Nhan L. , Swanson, Kristin R. , Boardman, Lisa A, Sun, Hongzhe , Wang, Junwen , Koohi-Moghadam, Mohamad, Swanson, Kristin R , Wang, Junwen , Koohi‐Moghadam, Mohamad , Borad, Mitesh J. , Boardman, Lisa A, Tran, Nhan L

Mayo Clinic

Bioinformatics | February 27, 2019 | Volume: 35 | Issue: 19 | Pages: 3812-3814

10.1093/bioinformatics/btz123 | PMID 30825371 Get It

Abstract Summary We present MetaMarker, a pipeline for discovering metagenomic biomarkers from whole-metagenome sequencing samples. Different from existing methods, MetaMarker is based on a de novo approach that does not require mapping raw reads to a reference database. We applied MetaMarker on whole-metagenome sequencing of colorectal cancer (CRC) stool samples from France to discover CRC specific metagenomic biomarkers. We showed robustness of the discovered biomarkers by validating in independent samples from Hong Kong, Austria, Germany and Denmark. We further demonstrated these biomarkers could be used to build a machine learning classifier for CRC prediction. Availability and implementation MetaMarker is freely available at https://bitbucket.org/mkoohim/metamarker under GPLv3 license. Supplementary information Supplementary data are available at Bioinformatics online.
Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
Tassorelli, Cristina , Ashina, Messoud , Becker, Werner J. , Ferrari, Michel D. , Goadsby, Peter J. , Wang, Shuu‐Jiun , Mandrekar, Jay , Goadsby, Peter J , Wang, Shuu-Jiun , Ashina, Messoud , Diener, Hans‐Christoph , Dodick, David W. , Silberstein, Stephen D. , Lipton, Richard B. , Pozo‐Rosich, Patricia

Mayo Clinic

Cephalalgia | February 26, 2019 | Volume: 39 | Issue: 6 | Pages: 687-710

10.1177/0333102419828967 | PMID 30806518 Get It

The quality of clinical trials is an essential part of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for controlled trials of drugs in migraine. Scientific and clinical developments in headache medicine led to second and third editions in 2000 and 2012, respectively. The current, fourth edition of the Guidelines retains the structure and much content from previous editions. However, it also incorporates evidence from clinical trials published after the third edition as well as feedback from meetings with regulators, pharmaceutical and device manufacturers, and patient associations. Its final form reflects the collective expertise and judgement of the Committee. These updated recommendations and commentary are intended to meet the Society's continuing objective of providing a contemporary, standardized, and evidence-based approach to the conduct and reporting of randomised controlled trials for the acute treatment of migraine attacks.
Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies
Flores, Shaney , Wang, Guoqiao , Hornbeck, Russ C. , Speidel, Benjamin , Joseph‐Mathurin, Nelly , Vlassenko, Andrei G. , Gordon, Brian A. , Klunk, William E. , Jack, Clifford R. , Farlow, Martin R. , Salloway, Stephen , Snider, Barbara J., Berman, Sarah , Roberson, Erik D. , Brosch, Jared R. , Jimenez-Velazques, Ivonne, Dyck, Christopher H. van , Yuan, Shauna H. , Jayadev, Suman , Gauthier, Serge , Hsiung, Ging‐Yuek Robin , Brooks, William S. , Fulham, Michael , Clarnette, Roger, Masters, Colin L. , Wallon, David , Hannequin, Didier , Dubois, Bruno , Pariente, Jérémie , Sánchez‐Valle, Raquel , Mummery, Catherine J. , Ringman, John M. , Klein, Gregory , Milosavljevic‐Ristic, Smiljana, Morris, John C. , Bateman, Randall J. , Jack, Clifford R , Gordon, Brian A , Hsiung, Gink-Yuek , Roberson, Erik , Sánchez-Valle, Raquel , Bateman, Randall J , Masters, Colin L , Joseph-Mathurin, Nelly , Morris, John C , Brooks, William , Su, Yi , Koeppe, Robert A. , Galasko, Douglas , Honig, Lawrence S. , Masellis, Mario , Bottlaender, Michel , McDade, Eric , Xiong, Chengjie , Benzinger, Tammie L.S. , Berman, Sarah

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | February 23, 2019 | Volume: 11 | Issue: 1 | Pages: 180-190

10.1016/j.dadm.2018.12.008 | PMID 30847382 Get It

Abstract Introduction Quantitative in vivo measurement of brain amyloid burden is important for both research and clinical purposes. However, the existence of multiple imaging tracers presents challenges to the interpretation of such measurements. This study presents a direct comparison of Pittsburgh compound B–based and florbetapir‐based amyloid imaging in the same participants from two independent cohorts using a crossover design. Methods Pittsburgh compound B and florbetapir amyloid PET imaging data from three different cohorts were analyzed using previously established pipelines to obtain global amyloid burden measurements. These measurements were converted to the Centiloid scale to allow fair comparison between the two tracers. The mean and inter‐individual variability of the two tracers were compared using multivariate linear models both cross‐sectionally and longitudinally. Results Global amyloid burden measured using the two tracers were strongly correlated in both cohorts. However, higher variability was observed when florbetapir was used as the imaging tracer. The variability may be partially caused by white matter signal as partial volume correction reduces the variability and improves the correlations between the two tracers. Amyloid burden measured using both tracers was found to be in association with clinical and psychometric measurements. Longitudinal comparison of the two tracers was also performed in similar but separate cohorts whose baseline amyloid load was considered elevated (i.e., amyloid positive). No significant difference was detected in the average annualized rate of change measurements made with these two tracers. Discussion Although the amyloid burden measurements were quite similar using these two tracers as expected, difference was observable even after conversion into the Centiloid scale. Further investigation is warranted to identify optimal strategies to harmonize amyloid imaging data acquired using different tracers.
Laminectomy alone versus fusion for grade 1 lumbar spondylolisthesis in 426 patients from the prospective Quality Outcomes Database
Chan, Andrew K. , Bisson, Erica F. , Bydon, Mohamad , Glassman, Steven D. , Foley, Kevin T. , Potts, Eric A. , Shaffrey, Christopher I. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Park, Paul , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S., Kerezoudis, Panagiotis , Chotai, Silky , DiGiorgio, Anthony M. , Haid, Regis W., Mummaneni, Praveen V. , Virk, Michael S.

Mayo Clinic

Journal of Neurosurgery: Spine | February 20, 2019 | Volume: 30 | Issue: 2 | Pages: 234-241

10.3171/2018.8.spine17913 | PMID 30544348 Get It

OBJECTIVEThe AANS launched the Quality Outcomes Database (QOD), a prospective longitudinal registry that includes demographic, clinical, and patient-reported outcome (PRO) data to measure the safety and quality of spine surgery. Registry data offer “real-world” insights into the utility of spinal fusion and decompression surgery for lumbar spondylolisthesis. Using the QOD, the authors compared the initial 12-month outcome data for patients undergoing fusion and those undergoing laminectomy alone for grade 1 degenerative lumbar spondylolisthesis.METHODSData from 12 top enrolling sites were analyzed and 426 patients undergoing elective single-level spine surgery for degenerative grade 1 lumbar spondylolisthesis were found. Baseline, 3-month, and 12-month follow-up data were collected and compared, including baseline clinical characteristics, readmission rates, reoperation rates, and PROs. The PROs included Oswestry Disability Index (ODI), back and leg pain numeric rating scale (NRS) scores, and EuroQol–5 Dimensions health survey (EQ-5D) results.RESULTSA total of 342 (80.3%) patients underwent fusion, with the remaining 84 (19.7%) undergoing decompression alone. The fusion cohort was younger (60.7 vs 69.9 years, p < 0.001), had a higher mean body mass index (31.0 vs 28.4, p < 0.001), and had a greater proportion of patients with back pain as a major component of their initial presentation (88.0% vs 60.7%, p < 0.001). There were no differences in 12-month reoperation rate (4.4% vs 6.0%, p = 0.93) and 3-month readmission rates (3.5% vs 1.2%, p = 0.45). At 12 months, both cohorts improved significantly with regard to ODI, NRS back and leg pain, and EQ-5D (p < 0.001, all comparisons). In adjusted analysis, fusion procedures were associated with superior 12-month ODI (β −4.79, 95% CI −9.28 to −0.31; p = 0.04).CONCLUSIONSSurgery for grade 1 lumbar spondylolisthesis—regardless of treatment strategy—was associated with significant improvements in disability, back and leg pain, and quality of life at 12 months. When adjusting for covariates, fusion surgery was associated with superior ODI at 12 months. Although fusion procedures were associated with a lower rate of reoperation, there was no statistically significant difference at 12 months. Further study must be undertaken to assess the durability of either surgical strategy in longer-term follow-up.
AIDS-Related Kaposi Sarcoma, Version 2.2019
Suneja, Gita , Ambinder, Richard F. , Ard, Kevin L. , Baiocchi, Robert A. , Cohen, Adam K. , Crysler, Oxana , Gupta, Neel K. , Gustafson, Chelsea, Hall, Andre, Johung, Kimberly L. , LaCasce, Ann S. , Lin, Chi , Menon, Manoj , Morgan, David , Nathwani, Nitya , Ratner, Lee , Rizza, Stacey A. , Sanchez, Julian , Taylor, Jeff , Tomlinson, Benjamin , Wang, Chia-Ching J., Dwyer, Mary A., CGC, Freedman-Cass, Deborah A., Rizza, Stacey , Ratner, Lee , Reid, Erin G , Barta, Stefan K , Carchman, Evie H. , Klopp, Ann H. , Mehta, Amitkumar , Noy, Ariela , Rudek, Michelle A. , Yendamuri, Sai S , CGC, Freedman-Cass, Deborah A., Ambinder, Richard F

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 20, 2019 | Volume: 17 | Issue: 2 | Pages: 171-189

10.6004/jnccn.2019.0008 | PMID 30787130 Get It

As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin’s lymphoma, Kaposi sarcoma, and cervical cancer), but the risk of Kaposi sarcoma in PLWH is still elevated about 500-fold compared with the general population in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AIDS-Related Kaposi Sarcoma provide diagnosis, treatment, and surveillance recommendations for PLWH who develop limited cutaneous Kaposi sarcoma and for those with advanced cutaneous, oral, visceral, or nodal disease.
Drug-associated vasculitis occurring after treatment with pembrolizumab
Tolaymat, Omar , Pinkston, Olga, Schenk, William B., Mergo, Patricia J. , Berianu, Florentina , Wang, Benjamin X. , Joseph, Richard W.

Mayo Clinic

Rheumatology | February 18, 2019 | Volume: 58 | Issue: 8 | Pages: 1501-1503

10.1093/rheumatology/kez051 | PMID 30892627 Get It

MRE11 UFMylation promotes ATM activation
Wang, Zhifeng , Gong, Yamin, Peng, Bin , Shi, R. , Zhao, Hongchang , Zhu, Min , Zhang, Haoxing , Zhou, Jianwei , Zhu, Wei‐Guo , Cong, Yu-Sheng , Xu, Xingzhi , Fan, Dan , Lou, Zhenkun

Mayo Clinic

Nucleic Acids Research | February 17, 2019 | Volume: 47 | Issue: 8 | Pages: 4124-4135

10.1093/nar/gkz110 | PMID 30783677 Get It

Year in Review in Cardiac Electrophysiology
Hussein, Ayman A. , Madhavan, Malini , Viswanathan, Mohan , Ceresnak, Scott R. , Park, David , Wang, Paul J. , Park, David S , Tzou, Wendy S. , Steinberg, Benjamin A. , Davis, Darryl Raymond , Kapa, Suraj

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | February 12, 2019 | Volume: 12 | Issue: 2 | Pages: No page available

10.1161/circep.118.007142 | PMID 30744401 Get It